Pacing Systems from Boston Scientific: ACCOLADE™, ESSENTIO™, VITALIO™,
INSIGNIO™, ADVANTIO™

INDICATIONS AND USAGE: Boston Scientific pacemakers are indicated for treatment of the following conditions: symptomatic paroxysmal or permanent second- or third-degree AV block, symptomatic bilateral bundle branch block, symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinusoidal [SA] block), bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias, neurovascular (vaso-vagal) syndromes or hypersensitive carotid sinus syndromes. Adaptive-rate pacing is indicated for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and/or level of physical activity. Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony. Dual-chamber modes are specifically indicated for treatment of the following: Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block, VT intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm, low cardiac output or congestive heart failure, secondary to bradycardia.

CONTRAINDICATIONS: These Boston Scientific pacemakers are contraindicated in patients who have a separate implanted cardioverter defibrillator (ICD) with transvenous leads. Use of certain pacing modes and/or features available in these Boston Scientific pacemakers is contraindicated for the following patients under the circumstances listed: unipolar pacing or use of the MV Sensor with a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) because it may cause inappropriate therapy or inhibition of appropriate S-ICD therapy. Minute Ventilation in patients with both unipolar atrial and ventricular leads, single-chamber atrial pacing in patients with impaired AV nodal conduction, atrial tracking modes for patients with chronic refractory atrial tachyarrhythmias (atrial fibrillation or flutter), which might trigger ventricular pacing, dual-chamber and single-chamber atrial pacing in patients with chronic refractory atrial tachyarrhythmias, asynchronous pacing in the presence of (or likelihood of) competition between paced and intrinsic rhythms.

WARNING: General: Read this manual thoroughly before implantation to avoid damage to the pulse generator and/or lead. Such damage can result in patient injury or death. For single patient use only. Do not reuse, reprocess, or resterilize. Always have external defibrillation equipment available during implant and electrophysiologic testing. Using multiple pulse generators could cause pulse generator interaction, resulting in patient injury or a lack of therapy delivery. In response to applicable nonrecoverable or repeat fault conditions, the pulse generator will switch irreversibly to Safety Core operation. Do not kink, twist, or braid the lead with other leads. Do not use atrial tracking modes in patients with chronic refractory atrial tachyarrhythmias. Lead Safety Switch should be programmed Off for patients with an ICD. Unipolar pacing due to Lead Safety Switch is contraindicated for patients with an ICD. Unipolar pacing due to RAAT is contraindicated and should be programmed Off for patients with an ICD. If programmed to a fixed atrial Sensitivity value of 0.15 mV, or a fixed sensitivity value of 2.0 mV or less in a unipolar lead configuration in any chamber, the pulse generator may be more susceptible to electromagnetic interference. Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device. Do not expose a patient to MRI scanning. Do not subject a patient with an implantable pulse generator and/or lead to diathermy since diathermy.

PRECAUTIONS: For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments; follow-up testing; cleaning and disposal; supplemental precautionary information. Advise patients to avoid sources of EMI. The pulse generator may inhibit pacing due to oversensing, or may switch to asynchronous pacing at the programmed pacing rate or at the magnet rate in the presence of EMI.

These pulse generators are contraindicated for use with a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) when implanted with bipolar leads and programmed to a bipolar pacing configuration. POTENTIAL ADVERSE EVENTS: Potential adverse events include, but are not limited to, the following: allergic/hypersensitivity reaction, death, erosion/migration, infection, fracture/breakage, lead or accessory breaks/fractures, ischemia, myocardial ischemia, myocardial infarction, arrhythmia, lead or accessory breaks/fractures, ischemia, myocardial ischemia, myocardial infarction, arrhythmia, lead or accessory breakage, fracture/breakage, infection, procedure-related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur. Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. Rev. A.
**New Efficiencies**

**Automatic Daily Monitoring**

- Improved Patient Compliance and Actionable Data
  Wireless, hands-free remote monitoring with LATITUDE™ NXT offers actionable data that enables earlier intervention
- Automatic and Customizable Alerts
  - Atrial arrhythmia burden
    \(>0, 0.5, 1, 3, 6, 12, 18, 24 \text{ hours}\)*
  - RV pacing percentage
    \(>10, 20, 30, 40, 50\)
  - Weight gain over time
    1-10 lbs in 1-7 days
- Automatic Device Interrogation
  - Interrogate the patient’s device on a schedule set by your clinic
  - No patient interaction required

**Leader in Longevity**

- Longest Projected Longevity
  The ESSENTIO Extended Longevity (EL) batteries provide the industry’s greatest battery capacity at 1.6 Amp hours with the longest projected longevity\(^1\)\(^,\)\(^3\)

\[
\text{12.1 YEARS}^*\]

- Efficient Circuitry
  - Greatest Battery Capacity

**New Features that Support Improved Efficiencies**

- Snapshot Capability
  Review real-time EGM/ECG data and pacing threshold test results
- Post-Operative System Test (POST)
  Improve workflow with an automatic system evaluation after implant
  - Lead impedances
  - Intrinsic amplitudes
  - Capture thresholds
- EasyView™ Header with Port Labels
  Aids with quick and easy identification of the appropriate port and verification of full lead insertion

**Sources**


\(^*\) Model L121 ESSENTIO EL devices

* Within a 24 hour period